Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DS5361b in Advanced Solid Tumors
NCT07182591Phase 1Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Oct 2025
- Primary completion
- Mar 2030
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of DS5361b in solid tumor, non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) (3 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Dose-Limiting Toxicities at Day 21, Treatment Emergent Adverse Events at 5 years and 1 more. Started Oct 2025; status: recruiting.
02
Drugs
DS5361b
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07182591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07182591.